5 November 2023
RNZ's Kim Hill discusses the results of the Malaghan Institute's phase 1 clinical trial.
Michele Leggott / Dr Robert Weinkove / Prof Carl June
Results have been released for Malaghan Institute's ground-breaking CAR T-cell cancer therapy trial, and they are promising.
The therapy reprogrammes a patient's own immune cells to recognise and kill cancer.
Discussing the treatment and trial are Professor Carl June from the University of Pennsylvania who pioneered the therapy and Dr Robert Weinkove, who leads Malaghan's CAR T-cell programme.
They are joined by writer and poet Michele Leggott, who is twelve months into the trial, for an update on her progress.
Related articles
Eradicating H. Pylori bacterial infection to reduce stomach cancer
30 October 2025
Read more
Developing next generation CAR T-cell therapies for more equitable cancer care
30 October 2025
Read more
Making local impact using global training in liver cancer research
30 October 2025
Read more
Faster CARs: overcoming cellular exhaustion to enhance cancer immunotherapies
29 October 2025
Read more
Improving immunotherapies for lung cancer
29 October 2025
Read more
Malaghan CAR T programme wins KiwiNet Research Commercialisation Award
23 October 2025
Read more